¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Stickler syndrome, type III"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • megacystis-megaureter syndrome
    °Å´ë¹æ±¤°Å´ë¿ä°üÁõÈıº
  • Meigs¡¯ syndrome
    ¸ÞÀ̱×ÁõÈıº
  • nephritic syndrome
    ÄáÆÏ¿°ÁõÈıº, ½ÅÀå¿°ÁõÈıº
  • nephrotic syndrome
    ÄáÆÏÁõÈıº, ½ÅÁõÈıº
  • neuroleptic malignant syndrome
    ½Å°æÀÌ¿ÏÁ¦¾Ç¼ºÁõÈıº
  • neurovascular syndrome
    ½Å°æÇ÷°üÁõÈıº
  • Noonan¡¯s syndrome
    ´©³­ÁõÈıº
  • nutritional deficiency syndrome
    ¿µ¾ç°áÇÌÁõÈıº
  • Ogilvie syndrome
    ¿À±æºñÁõÈıº
  • oral-facial-digital syndrome
    ÀÔ¾ó±¼¼Õ°¡¶ôÁõÈıº, ±¸°­¾È¸é¼öÁ·ÁöÁõÈıº
  • orbital apex syndrome
    ´«È®²ÀÁöÁõÈıº, ¾È¿Í÷´ÜÁõÈıº
  • organic brain syndrome
    ±âÁú¼º³úÁõÈıº
  • organic mental syndrome
    ±âÁú¼ºÁ¤½ÅÁõÈıº
  • Osler-Weber-Rendu syndrome
    ¿À½½·¯-¿þ¹ö-¶ûµÚÁõÈıº
  • obstructive sleep apnea syndrome
    Æó¼â¼ö¸é¹«È£ÈíÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • oral-facial-digital syndrome
    ÀÔ¾ó±¼¼Õ°¡¶ôÁõÈıº, ±¸°­¾È¸é¼öÁ·ÁöÁõÈıº
  • orbital apex syndrome
    ´«È®²ÀÁöÁõÈıº
  • organic brain syndrome
    ±âÁú³úÁõÈıº
  • organic mental syndrome
    ±âÁúÁ¤½ÅÁõÈıº
  • otocraniocephalic syndrome
    ±Í¸Ó¸®ÁõÈıº, À̵ΰ³ÁõÈıº
  • overlap syndrome
    °ãħÁõÈıº, ÁßøÁõÈıº
  • overwear syndrome
    °úµµÂø¿ëÁõÈıº
  • preleukemia myelodysplastic syndrome
    °ñ¼öÇü¼ºÀÌ»óÁõÈıº
  • pancoast syndrome
    ÆÇÄÚ½ºÆ®ÁõÈıº
  • peeling skin syndrome
    ÇǺιڸ®ÁõÈıº
  • phantom lover syndrome
    ȯ»ó¿¬ÀÎÁõÈıº
  • pluriglandular syndrome
    ¹µ»ùÁõÈıº, ¿©·¯»ùÁõÈıº
  • positive and negative syndrome
    ¾ç¼ºÀ½¼ºÁõÈıº
  • post-infarction syndrome
    °æ»öÈÄÁõÈıº
  • postelectric shock syndrome
    Àü±âÃæ°ÝÈÄÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • Klinefelters syndrome
    Ŭ¶óÀÎÆçÅÍÁõÈıº(¡­ñøý¦ÏØ)
  • Klippel Feli syndrome
    Ŭ¸®Æç-ÆäÀÏÁõÈıº.
  • Lambert-Eaton myasthenic syndrome
    ¶÷¹öÆ®-ÀÌÆ° ±Ù¹«·ÂÁõÁõÈıº
  • Landry Guillain Barre syndrome
    ¶õµå¸®-±æ·©-¹Ù·¹ÁõÈıº.
  • Laurence Moon Biedl syndrome
    ·Î·»½º-¹®-ºñµéÁõÈıº.
  • Lesch-Nyhan syndrome
    ·¹½¬ ´ÏÇÑ ÁõÈıº
  • Leser-Trelat syndrome
    ·¹Á¦¸£ Æ®·¼¶ó ÁõÈıº
  • Lhermittes syndrome, radiation-induced
    ¹æ»ç¼±À¸·Î À¯¹ßµÈ ·¹¹ÌÅ× ÁõÈıº
  • Libman Sachs syndrome
    ¸®ºê¸¸-ÀÛ½º ÁõÈıº.
  • Loeffler s eosinophilic syndrome
    ·ÚÇ÷¯È£»ê±¸ÁõÈıº
  • Loeffler s eosinophilic syndrome
    ·ÚÇ÷¯È£»ê±¸ÁõÈıº.
  • Loefflers syndrome
    ·ÚÇ÷¯ÁõÈıº
  • Lofgrens syndrome
    ·ÚÇÁ ±×¸° ÁõÈıº
  • Marchesanis syndrome
    ¸¶¸£ÄÉ»ç´ÏÁõÈıº
  • Marcus-Gunn syndrome
    ¸¶¸£Äí½º-°ÇÁõÈıº
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • type, wild
    ¾ß»ýÇü, ¾ß»ýÁÖ
  • undulant type
    ÆÄ»óÇü(÷îßÒúþ).
  • unstable type
    ºÒ¾ÈÀüÇü(ÝÕäÌïÒúþ).
  • water in oil type
    À¯Áß¼öÀûÇü(êúñéâ©îÙúþ).
  • well-type ionization chamber
    ¿ì¹°ÇüÀü¸®ÇÔ
  • wild type
    ¾ß»ýÇü(å¯ßæúþ).
  • abdominal muscle deficiency syndrome
    º¹±Ù°á¼ÕÁõÈıº(ÜÙÐÉÌÀáßñøý¦ÏØ).
  • absent pulmonary valve syndrome
    Æóµ¿¸ÆÆÇ°á¿©Áõ.
  • absent pulmonary valve syndrome
    Æóµ¿¸ÆÆÇ°á¿©Áõ.
  • absent testes syndrome
    °íȯ°á¿©ÁõÈıº
  • abstinence syndrome
    ±Ý´ÜÁõÈıº(Ð×Ó¨ñøý¦ÏØ).
  • acid aspiration syndrome
    À§»ê ÈíÀÔ ÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌÁõÈıº(ý­ô¸àõ Øóæ¹ÌÀù¹ñøý¦ÏØ)
  • acquired immunodeficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
DS dead air space; dead space; deep sedative; deep sleep; defined substrate; dehydroepiandrosterone sul...
ESS empty sella syndrome; endostreptosin; erythrocyte-sensitizing substance; euthyroid sick syndrome; ev...
FTS family tracking system; feminizing testis syndrome; fetal tobacco syndrome; fissured tongue syndrome...
HHS [Department of] Health and Human Services; Hearing Handicap Scale; hereditary hemolytic syndrome; hu...
HPS Hantavirus pulmonary syndrome; hematoxylin, phloxin, and saffron; Hermansky-Pudlak syndrome; high-pr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
Ad5 Adenovirus type 5
Ad 7 Adenovirus type 7
Ad9 Adenovirus type 9
ATII Alveolar type II
ATD Alzheimer Type Dementia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • deficient antibody syndrome
    Ç×ü °áÇÌ ÁõÈıº
  • deficit syndrome
    °áÇÌ ÁõÈıº
  • Demons-Meigs' syndrome
    µ¥¸ó½º-¸Þ±×½º ÁõÈıº
    ³­¼Ò ¼¶À¯Á¾À¸·Î È÷½ºÅ¸¹Î¿¡ ÀÇÇÑ ¾Æ³ªÇʶô½Ã Áõ»ó. ¼ö´ë»ç¿Í ±³Áú°èÀÇ º´º¯ ¹× Á¾¾çÀÇ È£¸£¸ó ÀÛ¿ë¿¡ ÀÇÇØ º¹¼ö¿Í Èä¼ö°¡ º´¹ßÇÑ´Ù.
  • denial-of-deficit syndrome
    °áÇÌ ºÎÁ¤ ÁõÈıº
  • Denny-Brown's syndrome
    µ¥´Ï-ºê¶ó¿î ÁõÈıº
    ³»°æµ¿¸Æ Æó»öÁõÀ̶ó°íµµ Çϸç, ºñ±³Àû ÀþÀº Ãþ¿¡ ¸¹Àº º´À¸·Î, °£Áú ºñ½ÁÇÑ ¹ßÀÛ, °¡º­¿î ¾ð¾î ÀåÇØ, ¹Ý½Å ºÒ¼ö µîÀÇ Áõ»óÀÌ Æ¯Â¡Àε¥, ³úµ¿¸Æ ÃÔ¿µÀ¸·Î °æµ¿¸ÆÀÇ Æó»öÀ» Áõ¸íÇÒ ¼ö ÀÖ´Ù.
  • dermatorheumatismal syndrome
    ÇǺΠ·ù¸¶Æ¼½º ÁõÈıº
  • Devies syndrome
    µ¥ºò ÁõÈıº
  • Di George's syndrome
    µð, ÁÒ¿ÀÁö ÁõÈıº
    1. Èä¼±ÀÌ Çü¼ºµÇÁö ¸øÇÏ´Â Èä¼± ¹«Çü¼ºÁõÀ» µ¿¹ÝÇϹǷΠÀÎÇØ ¹ß»ýÇÏ´Â ¼¼Æ÷ ¸Å°³¼º ¸é¿ªÀÇ °áÇÌÀÌ ³ªÅ¸³ª´Â Áúº´. 2. Èä¼±ÀÇ ¹«Çü¼º ³»Áö ÀúÇü¼º°ú ¼±Ãµ¼º ½ÉÁúȯ. ºÎ°©»ó¼± ÀÌ»óÁõÀ» ¼ö¹Ý½ÃŰ´Â ¼±Ãµ¼º ¼¼Æ÷¼º ¸é¿ª ºÎÀü ÁõÈıºÀÌ¸ç ¸· ž ¶§¿¡ º¼ ¼ö ÀÖ´Â À̰³ÀÇ ÀúÀ§, ¾î»ó±¸ ¾ç¾ÈÀÇ °Ý¸® µîÀÇ Æ¯À¯ ¾È¸ð¿Í ºÎ°©»ó¼± ±â´É Å»¶ô¿¡ ÀÇÇÑ Àú Ä®½· Ç÷Áõ, ¿ïÇ÷¼º ½ÉºÎÀü µî¿¡ ÀÇÇÏ¿© ÀǽÉÀ» °¡Áö°Ô µÇ°í Èä¼± ¹× T¼¼Æ÷ ±â´ÉÀÇ °Ë»öÀ¸·Îµµ Áø´ÜÀÌ ³»·ÁÁø´Ù. º´ÀÎÀ¸·Î¼­´Â ÀÌ»óÁ¦±â°ü »çÀÌÀÇ °ü·Ã¿¡¼­ Å»ý 12ÁÖ °æÀÇ ¹ß»ý ÀÌ»óÀ» »ý°¢ÇÒ ¼ö ÀÖ´Ù.
  • diencephalic-hypophysial syndrome
    °£³ú Çϼöü ÁõÈıº
    ¿äºØÁõ, Áö¹æÁõ, ¼º±â À§Ãà, ½Ã¸óÁ µîÀÇ ÃÑĪ. °£³ú, ƯÈ÷ ½Ã»ó ÇϺο¡´Â ¿©·¯ °¡Áö ÀÚÀ²½Å°æ ÁßÃß°¡ Àִµ¥, °£³ú ÇϼöüÀÇ ¿¬°áÀº ÇØºÎÇлóÀ¸·Î³ª ±â´É»óÀ¸·Îµµ ±ØÈ÷ ¹ÐÁ¢ÇÑ °ü°è°¡ ÀÖ´Â °ÍÀÌ ¸í¹éÇØÁ®¼­, Áö±Ý±îÁö ³úÇϼöü°èÀÇ Àå¾Ö·Î ¸»¹Ì¾Ï¾Æ »ý±ä´Ù°í »ý°¢µÇ¾î¿Â À§À庴 µîÀÇ Áõ¼¼´Â °£³ú ÁßÃßÀÇ Àå¾Ö¸¸À¸·Î »ý±ä´Ù´Â °ÍÀÌ ¹àÇôÁ³´Ù.
  • diffuse hemorrhagic syndrome
    ¹Ì¸¸¼º ÃâÇ÷¼º ÁõÈıº
  • Digeorge syndrome
    Digeorge ÁõÈıº
    À¯Àü¼º ¸é¿ª °á¼ÕÀÇ ÇÑ Á¾·ù·Î Èä¼± Çü¼º ºÎÀü°ú ¼¼Æ÷¼º ¸é¿ª ±â´ÉÀÇ °¨¼Ò·Î ³ªÅ¸³­´Ù.
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ ¼±Á¾ ÁõÈıº
  • dorsal midbrain syndrome
    ÈÄÁß³ú ÁõÈıº
  • double crush syndrome
    ÀÌÁß ºÐ¼â ÁõÈıº
  • Dresslers syndrome
    µå·¹½½·¯ ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
type II acrocephalosyndactyly type II acrocephalosyndactyly
type II cells Cuboidal cell's connected with the squamous pulmonary alveolar cell's and having in their cytoplasm lamellated bodies (cytosomes) that represent the source of the surfactant that coats the alveoli.
Synonym: granular pneumonocytes, type II cells.
(05 Mar 2000)
type II collagen Collagen unique to cartilage, nucleus pulposis, notochord, and vitreous body; it forms as thin highly glycosylated fibrils.
(05 Mar 2000)
type II diabetes <disease> An often mild form of diabetes mellitus of gradual onset, usually in obese individuals over age 35; absolute plasma insulin levels are normal to high, but relatively low in relation to plasma glucose levels; ketoacidosis is rare, but hyperosmolar coma can occur; responds well to dietary regulation and/or oral hypoglycaemic agents, but diabetic complications and degenerative changes can develop.
(05 Mar 2000)
type II dip Late deceleration of the foetal heart rate, 30 seconds or more after the height of uterine contraction, as displayed on a foetal monitor graph.
(05 Mar 2000)
type II error The statistical error (said to be of the second kind or beta error) made in testing an hypothesis when it is concluded that a treatment or intervention is not effective when it really is. Sometimes referred to as a false negative.
(12 Dec 1998)
type II familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of beta-lipoproteins, cholesterol, and phospholipids, but normal triglycerides; heterozygotes have mild lipid changes and are susceptible to atherosclerosis in middle age, but homozygotes have severe changes often with generalised xanthomatosis and xanthelasma, and frank clinical atherosclerosis as young adults. The primary defect is a deficiency of apoprotein of VLDL, and the disorder is divided into two classes: 1) type IIA, which has elevated LDL due to a deficiency of the receptor or a modified apolipoprotein B-100; 2) type IIB, which has elevated LDL and triglycerides; autosomal dominant inheritance.
Synonym: familial hyperbetalipoproteinaemia, familial hypercholesteraemic xanthomatosis, familial hypercholesterolaemia.
(05 Mar 2000)
type II hyperlipoproteinaemia <biochemistry> A relatively rare (7 out of 1,000) genetic disease in which there is elevation in the blood triglycerides, cholesterol and low density lipoprotein (LDL). Also called type II hyperlipoproteinaemia, familial hyperlipoproteinaemia or familial hypercholesterolaemia.
Origin: Gr. Haima = blood
(27 Sep 1997)
type II interferon <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
type II mortality <epidemiology> A mortality schedule in which all hosts are assumed to die at a constant rate. This constant rate is equal to the inverse of the life expectancy.
(05 Dec 1998)
type II mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism characterised by deficiency of iduronate sulfatase, with excretion of dermatan sulfate and heparan sulfate in the urine; clinically similar to Hurler's syndrome but distinguished by less severe skeletal changes, no corneal clouding, and X-linked recessive inheritance.
Synonym: type II mucopolysaccharidosis.
(05 Mar 2000)
type I interferon <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
type I mortality <epidemiology> A mortality schedule in which all hosts are assumed to live for a fixed number of years equal to the life expectancy.
(05 Dec 1998)
type IS mucopolysaccharidosis <syndrome> A hereditary metabolic disorder caused by a recessive gene which results in a deficiency of the enzyme alpha-L-iduronidase, which breaks down dermatan sulphate and heparan sulphate, two types of mucopolysaccharides (complex carbohydrates). Consequently, the mucopolysaccharides accumulate in the cells of the body and cause damage.
Symptoms include skeletal deformities, mental retardation, coronary artery disease, deafness, and stiff joints, among other things. There are mild and severe forms of the syndrome, the severe form is called Hurler syndrome, the mild form is called Scheie Syndrome, and children with an intermediate form have Hurler-Scheie Syndrome. Patients with the mild form generally suffer little to no mental retardation and survive to adulthood. There is presently no cure. Scheie's Syndrome is one of a number of related rare genetic mucopolysaccharide disorders, the most common being Hunter syndrome.
(09 Oct 1997)
type IVA,B mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism with excretion of keratan sulfate in urine; characterised by severe skeletal defects with short stature, severe deformity of spine and thorax, long bones with irregular epiphyses but with shafts of normal length, enlarged joints, flaccid ligaments, and waddling gait; autosomal recessive inheritance; type IV A mucopolysaccharidosis is due to an absence of galactose-1-sulfatase, while type IV B is due to a deficiency of a beta-galactosidase.
Synonym: Brailsford-Morquio disease, Morquio's disease, Morquio-Ullrich disease, type IVA, B mucopolysaccharidosis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
ÅëÇÕ°Ë»ö ¿Ï·á